We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image

MENSTRUAL CRAMPS TREATMENT MARKET ANALYSIS

Menstrual Cramps Treatment Market, By Drug Class (Analgesics, Anticholinergics, Non-steroidal anti-inflammatory drugs, Haematinics, and Others (Progestins, Among others)), By Type (Primary Dysmenorrhea and Secondary Dysmenorrhea), By Route of Administration (Oral, Injectable, Topical, Intrauterine, and Others (Intrauterine, Among others)), By Dosage Form (Tablet, Capsules, Suspension, and Others (Transdermal Patch, Among others)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

  • Published In : May 2023
  • Code : CMI5760
  • Pages :205
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Market News

Global Menstrual Cramps Treatment Market: Key Developments

On December 28, 2020, Myovant Sciences Ltd, a subsidiary of Sumitovant Biopharma Ltd, a biopharmaceutical company, and Pfizer. Inc., a U.S.-based multinational pharmaceutical and biotechnology corporation, collaborated for development and commercialization of Relugolix for treatment of heavy menstrual bleeding associated with uterine fibroids and endometriosis.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.